The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...
The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...
Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...
The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.
Pharma companies need to move beyond the “weight-loss Olympics” and focus on more durable treatments with fewer side effects, ...
A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked ...
Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback